Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US.

Joshua E Kessler, Kwon N Park,Amy J Grizzle,Jason T Hurwitz

Expert review of pharmacoeconomics & outcomes research（2023）

引用 0|浏览0

暂无评分

摘要

PD-L1 positive stage IV NSCLC treatment is a costly condition with annual direct medical costs of $3.01 billion. The primary cost driver was immunotherapy, making up 74.6% of the total cost.

查看译文

关键词

PD-L1,burden of illness,cost of illness,immunotherapy,non-small cell lung cancer,stage IV NSCLC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要